ORPHA:595133
Perivascular epithelioid cell neoplasm
Also known as: PEComa · Perivascular epithelioid tumour
Publications
3,018
Trials
8
Interventional, condition-specific
Researchers
1,092
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare soft tissue tumor characterized by distinctive perivascular epitheloid cells, often arranged radially around a vascular lumen, as well as spindled cells in variable proportion. Melanocytic and muscle markers are typically positive. The tumors have been reported in the uterus, falciform ligament, and large and small intestine, among others. Depending on their location, they may present as a painful or painless mass, or with vaginal bleeding. Tumors displaying infiltrative growth, marked hypercellularity, nuclear enlargement and hyperchromasia, high mitotic activity, atypical mitotic figures, and/or coagulative necrosis should be regarded as malignant.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006359
- MeSH:D054973
- UMLS:C1300127
- NCIT:C38150
Additional Mondo synonyms (5)
neoplasm with perivascular epithelioid cell differentiation · perivascular epithelioid cell neoplasm · perivascular epithelioid cell tumour · tumor with perivascular epithelioid cell differentiation · tumour with perivascular epithelioid cell differentiation
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,018 matched papers (2,030 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
8 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
3,018
3,018 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
3,018 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2,030 in the last 10 years · low confidence
Phrase hits: 3,018 · MeSH hits: 11
Who's working on it?
1,092
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Caliò A5 papers · 2026
Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.
Papers in Europe PMC - 02Martignoni G5 papers · 2026
Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy; Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Verona, Italy.
Papers in Europe PMC - 03Michal M5 papers · 2026
Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Prague.
Papers in Europe PMC - 04Zhang L5 papers · 2026
Daytime Comprehensive Care Unit, Peking University People's Hospital, Beijing, 100044, P. R. China.
Papers in Europe PMC - 05Agaimy A4 papers · 2026
Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany.
Papers in Europe PMC - 06Sangoi AR4 papers · 2026
Stanford Medical Center, Stanford Health Care, 300 Pasteur Drive, Stanford, CA, 94305, USA. asangoi2@yahoo.com.
Papers in Europe PMC - 07Argani P3 papers · 2026
Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Papers in Europe PMC - 08Cheng L3 papers · 2026
Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University and Brown University Health, Providence, RI, USA.
Papers in Europe PMC - 09Krcek R3 papers · 2026
Department of Radiation Oncology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Papers in Europe PMC - 10Li C3 papers · 2026
Department of Pathology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
8
interventional trials for this specific condition
8 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 27 July 2026
8 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 90.6th percentile).
low confidence · 90.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
8 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07467772·RECRUITING·Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Conditions: Uterine Sarcoma · Uterine Leiomyosarcoma · Endometrial Stromal Sarcoma · ESS·Matched via name phrase
- NCT03967834·RECRUITING·Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Conditions: Soft Tissue Sarcoma · Clear Cell Sarcoma · Epithelioid Sarcoma · Perivascular Epithelioid Cell Neoplasms·Matched via MeSH
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Perivascular epithelioid cell neoplasm" OR "PEComa" OR "Perivascular epithelioid tumour" OR "neoplasm with perivascular epithelioid cell differentiation" OR "perivascular epithelioid cell tumour" OR "tumor with perivascular epithelioid cell differentiation" OR "tumour with perivascular epithelioid cell differentiation"
MeSH descriptor terms unioned into the query: Perivascular Epithelioid Cell Neoplasms
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Perivascular epithelioid cell neoplasm" OR "PEComa" OR "Perivascular epithelioid tumour" OR "neoplasm with perivascular epithelioid cell differentiation" OR "perivascular epithelioid cell tumour" OR "tumor with perivascular epithelioid cell differentiation" OR "tumour with perivascular epithelioid cell differentiation" OR "Perivascular Epithelioid Cell Neoplasms"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 8 interventional · 1 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3018) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T18:50:30.464Z
